294) refined interpretation of uncertainty of treatment ranking. |
295) ound: Adherence to and the maintenance of treatment regimens are fundamental for pai |
296) Therefore, to design better treatment regimens for TB, we need to unde |
297) lled trials (RCTs) evaluating 5 different treatment regimens for genitourinary syndr |
298) All treatment regimens had comparable efficacy |
299) ettings for screening patients to improve treatment strategies in cervical cancer. |
300) or juxtaposing molecular subtype targeted treatment strategies with the adjuvant use |
301) and provides future insights for clinical treatment strategies. |
302) development of preclinical testing of new treatment strategies. |
303) Age, diet, disease state, and treatment adherence also influence drug re |
304) of interpersonal coordination to improve treatment adherence and reduce stigma, as |
305) oviral therapy and two explored issues of treatment adherence. |
306) osis and could help to develop an optimal treatment approach by an early detection. |
307) de effect profile of these AEDs, a recent treatment approach involves priority use o |
308) as the potential to inform a personalized treatment approach. |
309) Adropin treatment or transgenic adropin overexpres |
310) To date, there is no confirmed treatment or vaccine prevention strategy a |
311) today, there is no universal dengue fever treatment or vaccines unreservedly recomme |
312) f factors that are associated with poorer treatment outcome and inform the developme |
313) atment levels of perceived life stress on treatment outcome in a sample of 200 indiv |
314) ing blood is a significant factor for the treatment outcome in patients with locally |
315) udies published to date and difference in treatment protocols for TF-CBT used with p |
316) Development of treatment protocols specific to children w |
317) and caring and also on the use of medical treatment protocols. |
318) are an effective alternative to inpatient treatment that lead to sustained improveme |
319) For high-risk patients, the treatment that minimizes the risk of relap |
320) sent the hope for a new direction for HIV treatment that reduces adherence barriers |
321) Little is known about how the amount of treatment a person with aphasia receives i |
322) g signals for iron at 4 and 12 days after treatment, a significant decrease in peak |
323) physiology, pathophysiology, and disease treatment as they relate to gynecologic ma |
324) mbiont-free strain obtained by antibiotic treatment as well as genome analyses revea |
325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
|